Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02584933
Title Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Ceritinib

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

Additional content available in CKB BOOST